Biotech China 2014

Cancer Biology: Pfizer

Total Score People Score Events Score
116 102 71
Date Event Presentation Speakers
March 19, 2013 Discovery Chemistry Congress The Future of Formulation and Drug Delivery in Global Healthcare Provision Sven Stegemann
December 8, 2012 54th American Society of Haematology Annual Meeting and Exposition Career-Development Lunch Sessions David A. Roth
December 4, 2012 4th World Epigenetics Summit Epigenetic Protein Families: A New Frontier in Small Molecule Drug Discoverys Paul Fish
December 4, 2012 CGS – The Cancer Genome Summit Accelerating the Drug Development Pipeline using Cancer Genome Sequencing Mao Mao
December 9, 2011 2nd Oxford Symposium on Epigenetic Mechanisms in Health and Disease Sessions 4 | Novel Small molecule Inhibitors of KMT7, A Lysine Mono-Methyltransferase Caroline Benn
November 29, 2011 The 7th annual European Antibody Congress is the worldleading conference addressing critical scientific issues and strategic industry challenges associated with therapeutic mAb development. Free or total therapeutic monoclonal antibody concentration monitoring Bing Kuang
September 19, 2011 The Role of Biomarkers in Clinical Trials A core microRNA signature of lung inflammation in rat and man Sterghios Moschos
June 27, 2011 RNAi, miRNA & siRNA Second Chair’s Closing Remarks and Close of Day Two Sterghios Moschos
PANNEL DISCUSSION | Epigenetics in RNAi Sterghios Moschos
First Chair's Opening Remarks Sterghios Moschos
March 27, 2011 Autophagy (D1) mTOR at the Crossroads of Cancer Metabolism and Cancer Therapy Robert T. Abraham
February 24, 2011 Targeting P13K / mTOR Signaling in Cancer Targeting the PI3K-mTOR pathway with cancer therapeutics: More or less Robert T. Abraham
January 31, 2011 Biomarkers Summit STREAM TWO | BIOMARKERS FOR INHALED ANTI-INFLAMMATORY THERAPIES – SAMPLING THE LUNG Iain Kilty
STREAM ONE | URINARY BIOMARKERS IN THE CLINICAL PROGNOSIS AND EARLY DETECTION OF ACUTE KIDNEY INJURY (AKI) Mark Fidock
STREAM TWO | DEVELOPING PROOF-OF-PHARMACOLOGY BIOMARKERS Mark Fidock
Chairman's opening remarks Mark Fidock
January 13, 2011 Inaugural Antibody Drug Products CovX-Bodies: A New Scaffold for Antibody Conjugates Joel Desharnais
January 12, 2011 Antibodies for the 21st Century Immunoconjugates for Oncology: Fewer Barriers to Delivering Cytotoxicity Now? Alejandro D. Ricart
October 20, 2010 6th Annual Meeting of the Oligonucleotide Therapeutics Society Session III: Two Short (15 min) Abstract Talks Arthur M. Krieg
August 25, 2010 Co-Development of Drugs and Diagnostics Diagnostic Test to Screen Non-Small Cell Lung Cancer Tumors for the Presence of Gene Rearrangements Hakan Sakul
August 24, 2010 Enabling Point-of-Care Diagnostics - Moving Towards Rapid Diagnosis Chairperson’s Remarks Hakan Sakul
June 23, 2010 Structure-Based Drug Design An Enriched Structural Kinase Database to Enable Structure-Based Drug Discovery Natasja Brooijmans
May 20, 2010 Bioanalytical Challenges for Optimizing Protein Therapeutics Free and Total Immunoassays for Monoclonal Antibodies to Soluble Targets and Target as Biomarker Lindsay King
Design of Experiments: Case Studies from a Bioanalytical Lab Franklin Spriggs
The Impact of Shed Target Antigen on the Quantitation of Therapeutic mAb and its Pharmacokinetics Implication Bing Kuang
May 20, 2010 Antibody Optimization Antibody-Drug Conjugates to Improve Therapeutic Index Wei Liao
Optimization of a Monoclonal Antibody for Improved Anti-Tumor Efficacy Gerald Casperson
Chairperson’s Opening Remarks Gerald Casperson
May 19, 2010 Pre-Clinical / Clinical Development of Therapeutic Antibodies Species Selection: The Foundation of the Nonclinical Toxicology Program Marque Todd
May 4, 2010 Biomarker World Congress 2010 Pre-clinical Translational Biomarkers: Enabling Early Predictions Using PK/PD Mark Fidock
April 28, 2010 Kinase Inhibitor Chemistry Structural Bioinformatics-Based Prediction of Selectivity of a p38 MAP Kinase Inhibitor Li Xing
Discovery of PF-04577806, a Potent and Selective PKCbeta Inhibitor Hui Li
Kinetic Analysis of the Enzyme Mechanism and the Allosteric Inhibition of CHK1 Jacques Ermolieff
April 27, 2010 Fragment Based Drug Discovery Fragment Optimization of a Dynamic Target: Finding Non-peptidic Matter for the Ala-Val Subpockets XIAP Cathy Moore
Talk Title to be Announced Ye Che
April 27, 2010 Anti-inflammatories: Small Molecule Approaches Discovery of CP-690,550: A Potent and Selective JAK Inhibitor for the Treatment of Autoimmune Diseases and Renal Allograft Rejection Mark Flanagan
April 6, 2010 IBCs 5th Annual China 2010 Pharmaceutical R&D Summit China's Pharmaceutical Industry from the Insiders' Eyes Steve Yang
Chairperson's Opening Remarks Steve Yang
4 Simultaneous Global Development - What Does It Mean for China? Bradley Merchant
An MNC's Perspective on the Overall Capabilities of China's Biosimilars/FOB Development - A Comparison with US/EU Yining Zhao
Martin Mackay, Ph.D. Right Targets. Right Patients. Right Now. Martin Mackay
February 24, 2010 5th Annual Bioanalysis in Clinical Research Validating and implementing sensitive protein biomarker LC-MS/MS assays in clinical programs Hendrik Neubert
Interactive panel discussion: Regulated bioanalysis - focus on support of clinical studies Hendrik Neubert
November 6, 2009 Clinical Applications for Age Management Medicine Continental Breakfast Erik Kuja
October 13, 2009 Fourth Annual Drug Repositioning Summit Pfizer Indications Discovery: Separating the Wheat from the Chaff Michael Barratt
September 19, 2009 Nature Chemical Biology Symposium 2009: Chemical Biology in Drug Discovery Session chair: Carolyn Cho
August 18, 2009 Inaugural Novel Vaccines: Adjuvants & Delivery Systems Enhancing Vaccine Immunogenicity Through Use of TLR9 Agonists Risini D. Weeratna
Chairperson’s Remarks Bilikallahalli Muralidhara
Formulation and Stability of DNA (Plasmid) Based Therapeutics Bilikallahalli Muralidhara
August 5, 2009 Targets in Context - Linking Targets to Diseases Agenda Human Genetics and Disease Relevant Targets: Linking Clinical Outcomes to Targets Albert B. Seymour
RNAi in Practice Ð Assays and Screening in Mammalian Cells Steven Haney
Tissue Engineered Tumor Niches as Drug Testing Platforms Eric YH Park
August 5, 2009 Drug Safety Strategies to De-Risk Compounds Imaging Techniques for Assessing Toxicity in Primary Human Hepatocytes Eric Tien
Imaging for Hepatotoxicity Eric Tien
Drug-Induced Mitochondrial Dysfunction Yvonne Will
August 3, 2009 The Next Wave of Antibody Therapeutics Clinical Development of the IGF-IR inhibitor Figitumumab for the Treatment of Cancer Antonio Gualberto
August 3, 2009 Oligonucleotide Therapeutics - From Concept to Implementation Agenda Strategies for Developing RNAi Therapeutics(tentative title) Satish Chandran
June 16, 2009 7th Annual Comparability for Biologics Developing and validating a whole blood cytokine release assay Aparna Deora
June 16, 2009 4th Annual Cell Based Assays Tackling the challenges of ion channels: developing assays to bridge the gap between experiments and patients Dermot O' Callaghan
Opening remarks from the Chairperson Darren Cawkill
Big isn't always beautiful: effective hit identification using subset screening for ion channels Helen Boyd
Closing remarks from the Chairperson Darren Cawkill
June 9, 2009 RNAi for Target Identification and Validation I. Surveying RNAi Opportunities: From Tools to Therapies Arthur M. Krieg
Chairperson’s Remarks Albert B. Seymour
Human Genetic Approaches to Target Discovery and Validation: Starting With the Clinical Endpoint of Interest Albert B. Seymour
June 9, 2009 Third Annual Cardiotoxicity and Drug Safety Table Eight: New Insights Into Clinical Cardiac Safety Testing Sashi Nadanaciva
June 8, 2009 RNAi for Functional Screens OPTIMIZING RNAi DELIVERY FOR IN VITRO APPLICATIONS Stanley M Speaker
June 8, 2009 Tackling RNAi Delivery Chairperson’s Remarks C. Satishchandran
June 4, 2009 Structure-Based Drug Design Using Thermodynamic Information to Enhance Quality of Design in Lead Generation Andrew D. Scott
Thinking Out Loud, a Day One Closing Panel: Are we ready for a GPCR structural explosion? Tomi Sawyer
Improving the Quality of Structure-Based Virtual Screen by The Interaction-Focused Post-Docking Analysis Suo-Bao Rong, Brian S. Bronk
Chairperson’s Remarks Tomi Sawyer
June 1, 2009 Combination Products Introductory Remarks: Contemporary and Global Perspectives on Combo Product Lifecycle Management Makarand S. Jawadekar
April 7, 2009 Kinase Inhibitor Chemistry - Charting the Chemical Space Topic 1: discussing pre-clinical challenges Stephan K. Grant
From HTS to Clinical Compound: Discovery of Potent and Exquisitely Selective C-Met Inhibitor PF-4217903 Jingrong Jean Cui
Discovery and Preclinical Development of Novel Protein Kinase C Inhibitors Stefan Grant
December 4, 2008 BIT Life Sciences 2nd Annual World Congress of Gene-2008 (WCG 2008) Title: TBD :Track 2-3 Yuan-Hua Ding
December 1, 2008 9th Annual Conference E U R OT I D E S 2008 “20 years of oligonucleotide drug development - what do we have to show?” Arthur M. Krieg
TRACK 1: Immune activation by DNA and RNA, implications for hybridization-based oligo(ribo)nucleotide therapies Jörg Vollmer,
November 26, 2008 1. Veterinary Vaccines | 2. Veterinary Clinical Trials | 3. Companion Animal Products Dog obesity and medical treatment: is there a need for a medical treatment or is Pfizer Animal Health just dreaming? Patrick Loiseau,
October 12, 2008 15th North American Regional Meeting - International Society for the Study of Xenobiotics Advances and Applications in Prediction of Biotransformation Pathways | Golden West Deepak Dalvie
Overview on the Role of Biotransformation in Drug Discovery Deepak Dalvie
Drug Metabolites and Toxicity: Experimental Approaches to Help Focus on What is Important Scott Obach
Determining Cross-Species Exposure-Receptor Occupancy Relationships for a Dual-Pharmacology CNS Compound: An Exercise in Translational Pharmacology. Christopher L. Shaffer
Determining Cross-Species Exposure-Receptor Occupancy Relationships for a Dual-Pharmacology CNS Compound: An Exercise in Translational Pharmacology. Christopher L. Shaffer
Structures of CYP3A4 Ligand Complexes: How Does Pharma Integrate this Information? Michael R. Wester
Structures of CYP3A4 Ligand Complexes: How Does Pharma Integrate this Information? Michael R. Wester
April 30, 2008 Assessment of Immunogenicity in Clinical Trials Cell-Based Versus Non-Cell Based Assays to Characterize Neutralizing Antibodies Deborah Finco Kent
March 25, 2008 Mastering Medicinal Chemistry Discovery and Development of Potent and Highly Selective c-Met/ HGFR Inhibitors Robert Kania
March 25, 2008 R&D Risk Mitigation Adapting to a Shifting Industry: How Are Deals Evolving? Stefanie A Hansen
Expert Panel: PUTTING PERSONALIZED MEDICINE INTO CLINICAL PRACTICE: PERSPECTIVES FROM THE STAKEHOLDERS David Lester
March 25, 2008 Clinical Trials Asia Clinical Research Landscape in India Chandrashekhar Potkar
Recent Regulatory Changes in India Chandrashekhar Potkar
March 25, 2008 Preclinical Development Development of an in Vitro Cytokine Release Assay and its Predicative Value Jing Min
March 25, 2008 TRANSLATIONAL MEDICINE Challenges and Opportunities in Translational Oncology Dominic Spinella
Chairperson’s Remarks Dominic Spinella
February 19, 2008 MedChem Europe Improving Processes in Lead Optimisation Andreas Sewing
December 4, 2007 7th World Drug Discovery & Development Summit 2007 SYSTEMS BIOLOGY IN DRUG DISCOVERY AND DEVELOPMENT - FUTURE PROMISE AND APPLICATIONS Dr. David De Graaf
Conference room 2 HIGH CONTENT SCREENING Jinghai Xu
November 29, 2007 Cell Signalling and Novel Cancer Therapeutics Role of translational biology in MEK inhibitor development Judith Sebolt Leopold
November 15, 2007 Second Annual Drug Development India : Planning and Managing Drug Discovery & Development Activities Nov(15-16) CONTRIBUTION OF ACADEMIC INSTITUTES (13:30-15:00) Matthew T. Reding
CONTRIBUTION OF ACADEMIC INSTITUTES: INTERACTIVE PANEL Supply Chain Challenges and Solutions to Reduce Cycle Time (14:20-15:00) Matthew T. Reding
PROTECTING AND MANAGING YOUR IP (08:15-09:10) Mak Jawadekar
PROTECTING AND MANAGING YOUR IP: INTERACTIVE CO-PRESENTATION:Global Intellectual Property (IP) Strategy and IP Legislation: Current Trends and Progress in India (08:20-09:10) Mak Jawadekar
November 12, 2007 Well Characterized Biologicals - Continuous Evolution of Chemo- and Bioanalytical Approaches Nov(12 - 14) Chairperson's Opening Remarks (08:00-08:15) Ned Mozier
Assessing Structure/Function Relationships (08:15-10:45) Aparna Deora
Assessing Structure/Function Relationships :Protein Changes that Make a Difference: Measuring the Impact on Biopotency with Various Bioanalytical Methods (09:15-09:45) Aparna Deora
Causes and Assessment of Product and Process-Related Impurities (13:25-18:30) Peter J. Nicastro
Causes and Assessment of Product and Process-Related Impurities:Comparison of Techniques for Aggregate Measurement (14:00-14:30) Peter J. Nicastro
CMC Approaches to Specific and Emerging Biotech Products (09:15-10:45) Michael R Schlittler,
CMC Approaches to Specific and Emerging Biotech Products: Characterization of Synthetic Peptides for Biotechnology - Unique Challenges (09:15-09:45) Michael R Schlittler,
Process and Analytical Related Issues (15:30-17:00) Amit Banerjee
November 7, 2007 Srial II: Advances and Challenges Toward Major Diseases: Extension on New Hope Nov (07-13) Session 16: Protein and Peptide Drug Development (13:30-17:00) Anton Fliri, Xing Wang
Session 16: Studies on the Origin of Protein Network Topologies (14:50-15:10) Anton Fliri
Session 16: Analytical Challenges in Protein Therapeutics Development (13:30-13:50) Xing Wang
November 5, 2007 Second Annual Biomarkers Europe Nov (05-06) BIOMARKERS FOR EARLY CLINICAL TRIALS (08:00-12:15) Mark Fidock, Karthik Venkatakrishnan
BIOMARKERS FOR EARLY CLINICAL TRIALS: Biomarker-Based Quantitative Risk Assessment for CYP3A Induction DDI in Early Clinical Development (11:30-12:00) Karthik Venkatakrishnan
BIOMARKERS FOR EARLY CLINICAL TRIALS: Lost in Translation (10:30-11:00) Mark Fidock
BIOMARKER QUALIFICATION AND VALIDATION: A Cost Effectiveness Approach to the Qualification and Acceptance of Biomarkers (16:45-17:15) David E. Slavin
BIOMARKER QUALIFICATION AND VALIDATION (15:45-17:45) David E. Slavin
October 17, 2007 Exploring Next Generation Sequencing: Applications and Case Studies (Oct 17-18) Deep Sequencing: Deep Sequence Analysis of Clinically Relevant env Region Sequence Variants from HIV (13:35-14:05) Marilyn Lewis
Deep Sequencing (12:00-15:30) Marilyn Lewis
October 16, 2007 Inaugural Kinbase Inhibitors: Moving Forward into Clinical Studies Oct (16-17) Sensitivity and Selectivity (08:30-10:40) Deborah Moshinsky
Sensitivity and Selectivity: Kinase Inhibitor Selectivity: Panel Screening and Application to Drug Discovery (08:40-09:10) Deborah Moshinsky
Registration, Morning Coffee & Roundtable Discussion Sessions (07:30-08:30) Tomi Sawyer
Executive Panel: Delivering Drugs for Difficult Targets (08:40-09:40) Alexander Rod MacKenzie
October 16, 2007 Inaugural HDAC inhibitors: Meeting the Challenges of Chemical Development of HDAC Inhibitors Oct (16 -17) Keynote Session: Executive Panel: Delivering Drugs for Difficult Targets(08:40-09:40) Alexander Rod MacKenzie
October 16, 2007 Fifth Annual RNAi for Drug Discovery and Therapeutics - Best Practices from the Bench to the Clinic Oct (16-17) Keynote Introduction; Executive Panel: Delivering Drugs for Difficult Targets (08:40-09:40) Alexander Rod MacKenzie
October 15, 2007 2nd Annual Innovations in Clinical Trials: Implementations of Biomarkers (Oct15-16) BIOIMAGING FOR MONITORING RESPONSE TO THERAPY, DOSE SELECTION, ASSESSING MOLECULAR ACTIVITY AND RECEPTOR OCCUPANCY (08:00-13:30) David Lester
Chairperson’s Remarks (08:00-08:05) David Lester
The Use of Cardiovascular Imaging in Drug Development: From Preclinical to Diagnostic Applications (10:30-11:00) David Lester
October 15, 2007 Thirs Annual Quantitative PCR, MicroArrays, And Biologican Validation: Capturing the Complete Biological Story (Oct 15-17) Case Studies: Leveraging Multiple RNA Measurement Tools to Support Discovery Research Programs (16:00-16:30) Shelley Ann Des Etages
Case Studies (15:30-17:30) Shelley Ann Des Etages
October 15, 2007 Cambridge Healthtech Institute's Third Annual Mastering Process Chemistry Oct (15-17) CASE STUDIES OF PRACTICAL SYNTHESIS: Process Development and Scale-Up of AG035029, a Potent PPARg Agonist for Treatment of Type II Diabetes (13:40-14:10) Shu Yu
CASE STUDIES OF PRACTICAL SYNTHESIS (13:30-18:30) Shu Yu, Matt Weekly
CASE STUDIES OF PRACTICAL SYNTHESIS: From First Bulk to a Commercial Route: Evolution of the Torcetrapib Process (16:10-16:40) Matt Weekly
September 30, 2007 Bridging Pharma and IT - Leveraging Information Technology to Improve Productivity (Sep30-Oct2) BRIDGING DISCOVERY/DEVELOPMENT AND IT: An Integrated Desktop Computing Environment for Chemists (14:00-14:45) Daniel Ortwine, Robert Goulet
BRIDGING DISCOVERY/DEVELOPMENT AND IT (09:30-15:30) Julie Hughes, Daniel Ortwine, Robert Goulet
BRIDGING DISCOVERY/DEVELOPMENT AND IT: Developing of Enabling Informatics Technology in Support of the Development of Drug Candidates (09:30-10:15) Julie Hughes
BRIDGING DISCOVERY/DEVELOPMENT AND IT (10:45-15:15) Melinda Rottas, Peter F. Thadeio
BRIDGING DISCOVERY/DEVELOPMENT AND IT: One Company ~ 2 Worlds - Bridging Discovery and Development Information (10:45-11:30) Melinda Rottas, Peter F. Thadeio
September 27, 2007 Protein Expression Europe (Sep 27-28) Parallel Approaches Continued (09:00-11:40) Ciaran Cronin
Parallel Approaches Continued: A Model for Parallel Protein Production (10:40-11:10) Ciaran Cronin
Drug Discovery Applications (13:00-15:15) Stephen Irving
Drug Discovery Applications: Overcoming Challenges in Supplying Proteins for Structural Biology (14:15-14:45) Stephen Irving
September 17, 2007 Biomarker Discovery Summit: Bridging the Silos in Biomarker Discovery & Validation (Sep17-19) Third Annual Toxicity Biomarkers; TOXICITY BIOMARKER DISCOVERY (08:30-11:00) Frances Clemo
Third Annual Toxicity Biomarkers; TOXICITY BIOMARKER DISCOVERY: Preclinical Biomarkers of Hepatotoxicity: What’s new? (09:35-10:05) Frances Clemo
Pre-Conference Workshops; Biomarker Assay Development and Validation: Part I Tutorial FIT-FOR-PURPOSE BIOMARKER ASSAY DEVELOPMENT AND VALIDATION (08:00-12:00) Jean W Lee
July 7, 2007 Protein Kinases and Protein Phosphorylation Distinct and Overlapping actions of KSR1 and KSR2 In Vivo and In Vitro Marilyn Lewis
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.